$1.2 Billion is the total value of Sofinnova Investments, Inc.'s 61 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Natera Inc | $109,969,000 | -12.9% | 3,102,960 | 0.0% | 9.16% | -4.4% | |
| Cincor Pharma Inc | $105,013,000 | +7.4% | 5,573,949 | 0.0% | 8.74% | +17.9% | ||
| AVTE | Aerovate Therapeutics Inc | $58,748,000 | -14.7% | 3,758,686 | 0.0% | 4.89% | -6.4% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $46,464,000 | -20.8% | 499,824 | 0.0% | 3.87% | -13.1% | |
| VERA | Vera Therapeutics Inccl a | $43,299,000 | -42.1% | 3,181,442 | 0.0% | 3.61% | -36.4% | |
| YMAB | Y-mAbs Therapeutics Inc | $33,199,000 | +27.4% | 2,194,278 | 0.0% | 2.76% | +39.8% | |
| NXTC | Nextcure Inc | $12,558,000 | -3.3% | 2,671,856 | 0.0% | 1.05% | +6.1% | |
| OBSV | ObsEva SA | $7,647,000 | +6.6% | 4,749,623 | 0.0% | 0.64% | +17.1% | |
| AKUS | Akouos Inc | $7,106,000 | -1.3% | 1,515,074 | 0.0% | 0.59% | +8.4% | |
| BOLT | Bolt Biotherapeutics Inc | $5,619,000 | -25.5% | 2,754,437 | 0.0% | 0.47% | -18.3% | |
| NCNA | Nucana Biomedsponsored adr | $4,060,000 | -27.4% | 5,599,999 | 0.0% | 0.34% | -20.5% | |
| GRTX | Galera Therapeutics Inc | $4,009,000 | -45.4% | 3,083,712 | 0.0% | 0.33% | -40.0% | |
| Nucana Biomedordinary shares | $1,740,000 | -27.4% | 2,400,000 | 0.0% | 0.14% | -20.3% | ||
| GERN | Geron Corpcall | $1,550,000 | +14.0% | 1,000,000 | 0.0% | 0.13% | +25.2% | |
| SYBX | Synlogic Inc | $661,000 | -52.1% | 574,972 | 0.0% | 0.06% | -47.6% | |
| PDSB | PDS Biotechnology Corporation | $521,000 | -41.0% | 142,635 | 0.0% | 0.04% | -35.8% | |
| FUSN | Fusion Pharmaceuticals Inc | $194,000 | -68.0% | 78,066 | 0.0% | 0.02% | -65.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.